Press Releases

Date Title
1/6/20 Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/23/19 Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
12/13/19 Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
12/12/19 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
11/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/14/19 Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
11/7/19 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
11/5/19 Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
10/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 31 - 40 of 635